NANJING, China, May 9, 2011 /PRNewswire-Asia/ — Simcere
Pharmaceutical Group (“Simcere” or the “Company”) (NYSE:
SCR), a leading pharmaceutical company specializing in the
development, manufacturing, and marketing of branded and
proprietary pharmaceuticals in China, today announced that Shanghai
Celgen Bio-Pharmaceutical Co., Ltd. (“Shanghai Celgen”) , in which
it holds a 35% equity interest, has received new drug registration
approval for Qiangke, its Recombinant Human TNF Receptor-IgG Fusion
Protein for Injection. Qiangke is primarily used for in-patient
treatment of ankylosing spondylitis and holds strong market
potential. Shanghai Celgen is currently preparing for the upcoming
GMP inspection by the SFDA.
In addition, Simcere plans to purchase the land use rights to
65,300 square meters in Beijing’s Zhongguancun Innovation Park to
establish a regional R&D center and offices. The purchase will
allow Simcere to take advantage of the talent, technology, and
resources available in Beijing. Simcere has signed a
framework agreement with Beijing Strong Science Park Development
Co., Ltd. for this project.
About Simcere Pharmaceutical GroupSimcere Pharmaceutical
Group (NYSE: SCR, Simcere) is a leading pharmaceutical company
specializing in the development, manufacturing, and marketing of
branded generic and proprietary pharmaceuticals in China. In recent
years, Simcere has been focusing its strategy on the development of
innovative pharmaceuticals and first-to-market generics. The
Company has introduced an innovative anti-cancer medication Endu,
first-to-market generics such as Bicun and Anxin, and a
first-to-market medication Sinofuan. Simcere manufactures and sells
drugs in the oncological, cardiovascular, anti-inflammatory and
anti-infection therapeutical areas. Simcere concentrates its
research and development efforts on the treatment of diseases with
high i
‘/>”/>
